PathAI
AI-powered pathology platform to improve patient outcomes through precision diagnostics
Enterprise·Technical·Powered by PathAI (proprietary)·API available
Key strengths
AI-powered pathology algorithmsLarge proprietary pathologist contributor network (450+ board-certified pathologists)Extensive annotation dataset (32.5M+ annotations)FDA-cleared digital pathology platform (AISight® Dx)CE-IVDR marked platformBiomarker discovery and drug development supportCloud-native open platform enterprise workflow (AISight®)
Enterprise pricing
Boston, USA
Founded 2016
Facts verified against pathai.com on
Get alerts when PathAI changes
Free. We'll email you when pricing, the free tier, API access or open-source status changes.
No ratings yet
PathAI – Technical Documentation Notes
Developers and technical evaluators working with PathAI should be aware of the following platform characteristics:
- AISight® is architected as a cloud-native, open platform, designed to integrate into existing enterprise anatomic pathology workflows without requiring a closed ecosystem.
- AISight® Dx carries both FDA clearance and CE-IVDR marking, supporting compliant clinical deployment across US and European regulatory jurisdictions.
- The platform supports third-party algorithm integrations, with confirmed partners including Deep Bio, Paige, Visiopharm, and DoMore Diagnostics, indicating an open or semi-open API/plugin model for algorithm ingestion.
- PathAI's AI algorithms are trained on a proprietary annotation dataset of 32.5M+ annotations sourced from 450+ board-certified pathologists, providing a high-quality, expert-labeled training corpus.
- The platform is positioned to support biomarker discovery and drug development use cases, relevant for BioPharma technical and data science teams building computational pathology pipelines.
Alternatives
See all alternatives